Abstracts Archive - Page 1942 of 2607 - ACR Meeting Abstracts

Abstract Number: 1064 • 2015 ACR/ARHP Annual Meeting
Feasibility and Validity of Patient Reported Outcome Measurement Information System (PROMIS) in SLE
Shanthini Kasturi¹, Jayme C. Burket², Jessica Berman¹, Kyriakos A. Kirou¹, Alana B. Levine¹, Lisa R. Sammaritano¹ and Lisa Mandl^1,3, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Healthcare Research Institute, Hospital for Special Surgery, New York, NY, ³Department of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Accurate measurement of patient reported outcomes (PROs) is particularly important in SLE, a heterogeneous disease in which similar symptoms can have disparate impact across…
Abstract Number: 1065 • 2015 ACR/ARHP Annual Meeting
Atherosclerotic Vascular Events in a Multinational SLE Inception Cohort: Description and Predictive Risk Factors over a 15 Year Period
Murray Urowitz^1,2, Dafna Gladman¹, Nicole Anderson³, Jiandong Su¹ and Systemic Lupus Erythematosus International Collaborating Clinics (SLICC), ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: A large multicentre multinational inception cohort was established to study risk factors for atherosclerosis (AS) in SLE. We aim to describe all vascular events…
Abstract Number: 1066 • 2015 ACR/ARHP Annual Meeting
Temporal Trends and Outcomes of Acute Myocardial Infarction in Systemic Lupus Erythematosus Hospitalizations
Narender Annapureddy¹, Achint Patel², Rabi Yacoub³, Krishna Pakanati⁴, Shiv Agarwal⁵, Priya Simoes⁶, Sunil Kamat⁷, Alexandre Benjo⁸ and Girish Nadkarni⁹, ¹Rheumatology and Immunology, Vanderbilt University, Nashville, TN, ²Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Gateway Medical Center, Clarksville, TN, ⁵Cardiology, University of Arkansas Medical Sciences, Little Rock, AR, ⁶Internal Medicine, St.Lukes Roosevelt Hospital Center at Mount Sinai, New York, NY, ⁷Critical Care, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India, ⁸Ochsner Clinic Foundation, New Orleans, NY, ⁹Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Cardiovascular disease remains the most common cause of mortality in Systemic lupus erythematosus (SLE). Some studies suggest that mortality due to acute myocardial infarction…
Abstract Number: 1067 • 2015 ACR/ARHP Annual Meeting
Sex Differences in Rates of End-Stage Renal Disease and Death Among Medicaid Patients with Incident Lupus Nephritis
Anna R. Broder¹, Candace H. Feldman², Anand Kumthekar³, Michail Alevizos⁴, Hongshu Guan⁵, Medha Barbhaiya⁶ and Karen H. Costenbader⁷, ¹Rheumatology-Forchheimer 701N, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Medicine, Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ⁴Medicine, Albert Einstien College of Medicine/Jacobi Medical Center, Bronx, NY, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Internal Medicine, Weill Cornell Medical College, New York, NY, ⁷Rheumatology, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Prior studies suggest that males with lupus nephritis (LN) may have worse outcomes than females. However, the majority of these studies, are from tertiary-care…
Abstract Number: 1068 • 2015 ACR/ARHP Annual Meeting
Assessment of 10-Year Risk of Myocardial Infarction or Stroke in SLE
Michelle Petri¹ and Laurence S Magder², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD
B Background/Purpose: In 2013 the American College of Cardiology (ACC) and the American Heart Association (AHA) developed a new formula to estimate the 10-year risk…
Abstract Number: 1069 • 2015 ACR/ARHP Annual Meeting
Child’s HLA-DRB1 Genotype Increases Maternal Risk of Systemic Lupus Erythematosus: Results from the Mother-Child Immunogenetic Study in Autoimmunity
Giovanna I. Cruz¹, Xiaorong Shao², Hong L. Quach², Janelle Noble³, Nikolaos Patsopoulos⁴, Michael Busch⁵, Darrell Triulzi⁶, Wendy S.W. Wong⁷, Benjamin Solomon⁷, John Niederhuber⁷, Lindsey A. Criswell⁸ and Lisa F. Barcellos², ¹School of Public Health, University of California, Berkeley, Berkeley, CA, ²Genetic Epidemiology and Genomics Laboratory, University of California, Berkeley, Berkeley, CA, ³Children's Hospital Oakland Research Institute, Oakland, CA, ⁴Division of Genetics, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁵Blood Systems Research Institute, San Francisco, CA, ⁶Institute of Transfusion Medicine, University of Pittsburgh, Pittsburgh, PA, ⁷Division of Medical Genomics, Inova Translational Medicine Institute, Falls Church, VA, ⁸Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA
Background/Purpose: SLE [MIM 152700] disproportionately affects women of reproductive age and pregnant patients are more likely to experience flares. Fetal microchimerism (FMC), or the persistence…
Abstract Number: 1070 • 2015 ACR/ARHP Annual Meeting
CD 14(C-159T) Polymorphism and Soluble CD14 Are Associated with Increased Disease Activity and Nephritis in SLE
Sarit sekhar Pattanaik¹, Aditya kumar Panda², Rashmi ranjan Sahoo¹, Rina Tripathy³ and Bidyut kumar Das¹, ¹Medicine, SCB Medical College, Cuttack, India, ²Centre for Life science, Central University of Jharkand, Ranchi, India, ³Biochemistry, SCB Medical College, Cuttack, India
Background/Purpose: Cluster of differentiation 14 (CD14) plays an important role in innate immune system as a co-receptor in TLRs (2, 4, 7 and 9) signaling.…
Abstract Number: 1071 • 2015 ACR/ARHP Annual Meeting
Single-Cell RNA Sequencing of Human Podocytes, Endothelial Cells, and Tubular Cells Identifies Markers and Gene Profiles Differentiating Class IV and Class V Renal Disease in Lupus Nephritis
Evan Der¹, Kemal Akat², Robert Clancy³, Beatrice Goilav⁴, Anna R. Broder⁵, H. Michael Belmont⁶, Peter M. Izmirly⁷, Nicole Jordan⁸, Tao Wang⁹, James Pullman¹⁰, Daniel Schwartz¹⁰, Ming Wu¹¹, Thomas Tuschl², Jill P. Buyon³ and Chaim Putterman¹², ¹Albert Einstein College of Medicine, Bronx, NY, ²Rockefeller University, New York, NY, ³Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Division of Nephrology, Children's Hospital at Montefiore, Bronx, NY, ⁵Rheumatology-Forchheimer 701N, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ⁶Hosp for Joint Disease, New York, NY, ⁷Rheumatology, NYU School of Medicine, New York, NY, ⁸Montefiore Medical Center, New York, NY, ⁹Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY, ¹⁰Pathology, Albert Einstein College of Medicine, Bronx, NY, ¹¹Pathology, New York University School of Medicine, New York, NY, ¹²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Currently, classification and treatment decisions in lupus nephritis (LN) are largely based on renal histology. Transcriptome analysis may accurately differentiate types of renal involvement,…
Abstract Number: 1072 • 2015 ACR/ARHP Annual Meeting
Baseline Gene Expression Profiles in 1760 Patients from Two Phase III Trials of BAFF/BLyS Blockade in SLE
Robert W Hoffman¹, Joan T Merrill², Marta E. Marta Alarcón Riquelme³, Michelle Petri⁴, Ernst R Dow⁵, Eric Nantz⁶, Laura K Nisenbaum⁵, Krista M Schroeder⁶, Wendy J Komocsar⁶, Narayanan B Perumal⁵, Matthew D Linnik⁶, Guilherme V Rocha⁶ and Richard E Higgs⁶, ¹Immunology-Medical, Eli Lilly and Company, Indianapolis, IN, ²OMRF, Oklahoma, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Johns Hopkins Lupus Center, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Eli Lilly and Company, Indiananpolis, IN, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Elevated Type-I interferon (IFN) signature characterizes at least 50% of adults with SLE and has been associated with autoantibodies and more severe disease in…
Abstract Number: 1073 • 2015 ACR/ARHP Annual Meeting
B Cell Subsets Are Epigenetically and Transcriptionally Dysregulated in Systemic Lupus Erythematosus
Emily Blalock¹, Chris Scharer², Ben Barwick², Scott Jenks³, Bridget Neary³, Jeremy Boss² and Ignacio Sanz^3,4, ¹Emory University School of Medicine, Atlanta, GA, ²Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, ³Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁴Medicine, Emory University, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by multiple B cell abnormalities, including the production of autoantibodies, a major contributing factor to disease pathogenesis. Epigenetic…
Abstract Number: 1074 • 2015 ACR/ARHP Annual Meeting
DNA Methylation Patterns in Naïve CD4+ T Cells Identify Epigenetic Susceptibility Loci for Malar Rash and Discoid Rash in Systemic Lupus Erythematosus
Paul Renauer¹, Patrick Coit¹, Matlock A. Jeffries², Joan T. Merrill³, W Joseph McCune⁴, Kathleen Maksimowicz-McKinnon⁵ and Amr H. Sawalha⁶, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ⁵Rheumatology, Henry Ford Hospital, Detroit, MI, ⁶Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by heterogeneous clinical manifestations, autoantibody production, and epigenetic dysregulation in T cells. We sought…
Abstract Number: 1075 • 2015 ACR/ARHP Annual Meeting
The Scleroderma Lung Study II (SLS II) Shows That Both Oral Cyclophosphamide (CYC) and Mycophenolate Mofitil (MMF) Are Efficacious in Treating Progressive Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc)
Philip J. Clements¹, Donald Tashkin¹, Michael Roth¹, Dinesh Khanna², Daniel E. Furst³, Chi-hong Tseng¹, Elizabeth R. Volkmann¹ and Robert Elashoff⁴, ¹Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of Michigan, Ann Arbor, MI, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Biomath, University of California Los Angeles, David Geffen School Of Medicine, Los Angeles, CA
Background/Purpose: Demonstrate that the course of forced vital capacity (FVC) over 2-years was better in SSc patients with symptomatic ILD treated with oral MMF for…
Abstract Number: 1076 • 2015 ACR/ARHP Annual Meeting
Safety and Tolerability of Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth R. Volkmann¹, Michael Roth², Robert Elashoff³, Philip J. Clements¹, Daniel E. Furst², Dinesh Khanna⁴, Jonathan Goldin⁵, Donald Tashkin¹ and Scleroderma Lung Study II Group, ¹Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁴Medicine, University of Michigan, Ann Arbor, MI, ⁵David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Although cyclophosphamide (CYC) demonstrated beneficial treatment effects at…
Abstract Number: 1077 • 2015 ACR/ARHP Annual Meeting
High Levels of CCL-18 Are Associated with Deterioration of Lung Function, Increased Annual Fibrosis Progression Rate and Decreased Survival in Systemic Sclerosis
Anna-Maria Hoffmann-Vold^1,2, Anders Heiervang Tennøe², Oyvind Midtvedt¹, Torhild Garen³, May Brit Lund⁴, Trond Mogens Aalokken⁵, Cathrine Brunborg⁶, Thor Ueland² and Øyvind Molberg⁷, ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²Institute of clinical medicine, University of Oslo, Oslo, Norway, ³Rheumatology, Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Respiratory Diseases, Oslo University Hospital, Oslo, Norway, ⁵Radiology, Oslo University Hospital, Oslo, Norway, ⁶Biostatistics, Epidemiology and Health Economics, Oslo University Hospital, Oslo, Norway, ⁷Department of Rheumatology, Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway
Background/Purpose: Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD), but biomarkers for individual risk stratification are largely missing. There is an…
Abstract Number: 1078 • 2015 ACR/ARHP Annual Meeting
CXCL4 Does Not Predict Extent or Progression of Interstitial Lung Disease in Systemic Sclerosis
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Michael Roth¹, Chi-hong Tseng¹, Holly LeClair², Philip J. Clements¹, Daniel E. Furst³, Maureen D Mayes⁴, Julio Charles⁵, Dinesh Khanna⁶, Robert Elashoff⁷, Shervin Assassi⁸ and Scleroderma Lung Study II Group, ¹Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴University of Texas - Houston Medical School, Houston, TX, ⁵Internal Medicine/Rheumatology, University of Texas - Houston Medical School, Houston, TX, ⁶University of Michigan, Ann Arbor, MI, ⁷Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁸Rheumatology, University of Texas Medical School at Houston, Houston, TX
Background/Purpose: Increased circulatory levels of the chemokine CXCL4 have been associated with the presence of pulmonary fibrosis (PF) by HRCT in an observational study of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].